|
Originally published In Press as doi:10.1074/jbc.M005508200 on September 19, 2000
J. Biol. Chem., Vol. 275, Issue 51, 40252-40257, December 22, 2000
Decreased Glucose Transporter Expression Triggers
BAX-dependent Apoptosis in the Murine Blastocyst*
Maggie M-Y
Chi,
Joyce
Pingsterhaus,
Mary
Carayannopoulos , and
Kelle H.
Moley§
From the Departments of Obstetrics/Gynecology and Cell Biology and
Physiology, Washington University School of Medicine, St. Louis,
Missouri 63110
Received for publication, June 22, 2000, and in revised form, September 13, 2000
 |
ABSTRACT |
We report that a decrease in facilitative glucose
transporter (GLUT1) expression and reduced glucose transport trigger
apoptosis in the murine blastocyst. Inhibition of GLUT1
expression either by high glucose conditions or with antisense
oligodeoxynucleotides significantly lowers protein expression and
function of GLUT1 and as a result induces a high rate of apoptosis at
the blastocyst stage. Similar to wild-type mice, embryos from
streptozotocin-induced diabetic Bax / mice experienced
a significant decrease in glucose transport compared with embryos from
non-diabetic Bax / mice. However, despite this
decrease, these blastocysts demonstrate significantly fewer apoptotic
nuclei as compared with blastocysts from hyperglycemic wild-type mice.
This decrease in preimplantation apoptosis correlates with a decrease
in resorptions and malformations among the infants of the hyperglycemic
Bax / mice versus the Bax +/+
and +/ mice. These findings suggest that hyperglycemia by decreasing
glucose transport acts as a cell death signal to trigger a
BAX-dependent apoptotic cascade in the murine blastocyst. This work also supports the hypothesis that increased apoptosis at a
blastocyst stage because of maternal hyperglycemia may result in loss
of key progenitor cells and manifest as a resorption or malformation,
two adverse pregnancy outcomes more common in diabetic women.
 |
INTRODUCTION |
In prior studies, it has been shown that maternal hyperglycemia
results in down-regulation of the embryonic facilitative glucose transporters (GLUT),1 GLUT1,
GLUT2, and GLUT3, at the blastocyst stage of mouse development (1).
Culturing two-cell embryos for 72 h in high concentrations of
glucose (30 or 52 mM) likewise causes a decrease in the
expression of these facilitative transporters at the mRNA and
protein levels. This decrease in transporter expression leads to a
significant drop in intraembryonic free glucose levels in blastocysts
obtained from mice made hyperglycemic by streptozotocin injection or
after culturing two-cell embryos from normal mice in high glucose.
Blastocysts cultured under similar conditions also experience a 6-fold
increase in expression of the proapoptotic protein BAX, as compared
with controls and undergo increased apoptosis (2). Approximately 40%
of all nuclei from embryos from hyperglycemic mothers showed evidence
of terminal dUTP nick-end labeling or TUNEL-positive staining compared
with less than 10% among controls. This apoptotic event requires BAX
expression because blastocysts recovered from diabetic Bax
/ mice are resistant to the hyperglycemia-induced apoptosis.
Similarly, the hyperglycemia-induced event is inhibited partially with
either the caspase inhibitor z-Val-Ala-Asp-fluoromethylketone (zVAD-FMK), or the ceramide synthase inhibitor, fumonisin B1, strongly
suggesting that these apoptosis-associated pathways are involved.
Apoptosis at this developmental stage may manifest later in pregnancy
as a malformation or, if a significant cell loss occurs, as a
miscarriage. Both these adverse pregnancy outcomes occur more
frequently in infants of diabetic women (3-5) and thus
hyperglycemia-induced apoptosis at this preimplantation stage may
explain the increased incidence of these pregnancy complications.
In these experiments, we hypothesize that the hyperglycemia-induced
decrease in glucose transport is responsible for triggering apoptosis.
This phenomenon has been described in other cell systems (6-9). To
test this hypothesis, we investigated the role of presumed upstream and
downstream components. First, we examined whether blocking GLUT1
expression with antisense oligonucleotides at the blastocyst stage
leads to apoptosis. This would suggest that decreased intracellular
glucose and not hyperglycemia per se triggers the death
cascade. Second, we examined whether BAX expression is downstream of
glucose transport using a Bax null model. In agreement with our initial hypothesis, we would predict that BAX expression is downstream of glucose transport and thus maternal hyperglycemia would
have the same effect of decreasing transport in embryos from
Bax / mice as seen in embryos from Bax +/+
mice. However, these embryos because of BAX deficiency would not
undergo apoptosis.
We also hypothesize that a glucose-induced increase in apoptosis at
this developmental stage may manifest later in pregnancy as a
malformation or, if a significant cell loss occurs, as a miscarriage.
To test this hypothesis we examined the effect of maternal diabetes in
the Bax-deficient mice on fetal malformations and pregnancy
resorptions. We know from previous work that lack of BAX expression
protects the blastocyst from glucose-induced apoptosis (2). Thus, if
this preimplantation event manifests later in pregnancy as a
miscarriage or malformation, these Bax null mice should
experience fewer reproductive complications of maternal hyperglycemia.
 |
EXPERIMENTAL PROCEDURES |
Embryo Recovery and Culture--
Embryos were recovered as
described previously (1). In brief, female mice (B6 × SJL F1,
Jackson Laboratories, Bar Harbor, ME) of 4-6 weeks of age were given
free access to food and water and were maintained on a 12:12 h
light/dark cycle. Superovulation was achieved with an intraperitoneal
injection of 10 IU/animal of pregnant mare serum gonadotropin (Sigma
Chemical) followed later by 10 IU/animal of human chorionic
gonadotropin (hCG, Sigma Chemical). Female mice were mated with males
of proven fertility overnight after hCG injection. Mating was confirmed
by identification of a vaginal plug.
Animals were killed by cervical dislocation at 48 h after hCG
administration and mating. Two- and four-cell embryos were obtained by
flushing dissected uterine horns and ostia as described previously. The
embryos were then immediately placed in human tubal fluid (HTF) medium
(Irvine Scientific) containing 0.25% BSA (Sigma, fraction V) and
cultured at 37 °C in an atmosphere of 5% CO2, 5%
O2, and 90% N2 for 24 h. Four-cell
embryos were exposed to 0.01% lysolecithin for 30 min and then
cultured for a further 48 h in one of the following conditions: 52 mM D-glucose, 52 mM L-glucose, 5 µM GLUT1 sense oligonucleotide
(S = ATGGAGCCCAGCAGCAAGAAG), or 5 µM GLUT1 antisense
oligonucleotide (AS = CTTCTTGCTGCTGGCTCGAT). The
oligodeoxynucleotides were modified to contain phosphorothioate linkages. In a previous study, this GLUT1 antisense oligonucleotide had
been used successfully in a preimplantation model to decrease protein
expression (10).
Western Analysis to Quantitate Embryo GLUT1
Protein--
Blastocysts were collected in groups of 200, added to 2×
sample buffer, subjected to 7.5% SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose. GLUT1 was then
detected using a polyclonal mouse Glut1 antibody (1:500, gift of Dr.
Mike Mueckler, Washington University School of Medicine).
125I-Labeled goat anti-rabbit IgG was used as the secondary
antibody. Radioactive bands were quantitated using a PhosphorImager SI
Analyzer (Molecular Dynamics).
Immunofluorescent Labeling to Quantitate Protein
Expression--
Immunofluorescence staining techniques have been
described for embryo preparations previously (1). All labeling was
performed in microdroplets. Blastocysts were fixed in 3% neutral
buffered formaldehyde for 30 min and then permeabilized with 0.1%
Tween 20 for 10 min. The embryos were then blocked by incubating for 60 min in 20% donkey serum in phosphate-buffered saline containing 2%
bovine serum albumin (PBS/BSA). Embryos were then washed three times
for 10 min each in PBS/BSA, incubated in the affinity-purified primary
antibody (polyclonal anti-mouse GLUT1) at a dilution of 15 µg/ml for
60 min. The embryos were then washed three times for 10 min each in
PBS/BSA and incubated with the secondary antibody, fluorescein
isothiocyanate (FITC)-labeled goat anti-rabbit IgG (Chemicon, Temecula,
CA) at a concentration of 1:80 followed by propidium iodide at a
concentration of 0.01 mg/ml for 20 min. Propidium iodide stains all
nuclei red. Finally the embryos were washed three times for 10 min each
in PBS/BSA and mounted in drops of Vectoshield (Vecto Labs, Burlingame,
CA) under a supported coverslip. Fluorescence was detected with a
Bio-Rad MRC-600 laser-scanning confocal microscope. Confocal images
were taken at × 63 magnification. Total fluorescence per embryo
was expressed as a number/area using NIH image (version 1.60). Similar
fluorescence ratios were derived for preimmune serum images and
subtracted from the GLUT1 images to generate a total fluorescence
value. These experiments were performed in triplicate with 7-10
blastocysts per group for each experiment.
2-Deoxyglucose Uptake and Free Glucose Assay--
To confirm
that the antisense oligoprobe blocked GLUT1 function as well as
expression, glucose uptake was measured using a nonradioactive
microanalytic procedure described previously (1, 11). In brief,
blastocysts after 72 h of culture were incubated at 25 °C in
200 µM 2-deoxyglucose (DG) for 15 min, washed in DG- and
BSA-free buffer for 1 min, and then were quick-frozen on a glass slide.
After freeze-drying overnight, the embryos were extracted in microliter
volumes under oil and assayed for DG and DG6P as described previously.
The final measurements are expressed as picomoles per embryo per 15 min. Experiments were performed in triplicate on 10-15 individual
embryos per group for each experiment. For the intraembryonic glucose
measurements, embryos were treated in the same manner as above and free
glucose levels were measured on individual blastocysts as described
previously (1, 11).
Terminal dUTP Nick End Labeling (TUNEL) Assays to Detect
Apoptosis in Blastocysts--
This technique has been described
previously for murine blastocysts (2, 12). Fixed blastocysts were
counterstained with propidium iodide to label all nuclear DNA and
fragmented DNA was end-labeled with FITC-labeled dUTP using terminal
transferase (cell death in situ kit, Roche Molecular
Biochemicals). The embryos were then observed using confocal
immunofluorescent microscopy (Bio-Rad MRC-600). A complete z-series was
performed for each blastocyst to ensure that each nucleus was sampled
and counted. The degree of apoptosis is expressed as % TUNEL-positive
nuclei (green channel) per total nuclei (red channel) per embryo. These experiments were performed in triplicate with 7-10 blastocysts per
group for each experiment.
Induction of Hyperglycemia in Mice and Preimplantation
Studies--
Bax / , +/ , and +/+ female mice were made
hyperglycemic by a single intraperitoneal injection of streptozotocin
(Sigma) dissolved in sodium citrate, pH 4.4, at a dose of 190 mg/kg as described previously (1, 13). Blood glucose levels were checked with
tail blood using a HemoCue B-glucose analyzer (Angelholm, Sweden) at
least four days following the injection. Blood glucose levels of
greater than 200 mg/dl were considered hyperglycemic. The hyperglycemic
and non-hyperglycemic control mice were superovulated and mated with
either Bax +/ males (for the Bax +/
and / females) or Bax +/+ males (for the Bax
+/+ females). Bax / males are infertile, and thus
Bax heterozygote males must be mated with Bax
null females (14). Embryos were recovered 96 h after mating. For
glucose uptake measurements, single embryo microfluorometric assays
were performed as described. For the apoptosis measurements, the
blastocysts were fixed in 3% paraformaldehyde, permeablized with 0.1%
Tween 20 and assayed for apoptosis by TUNEL as described.
Recovery of Day 14 Embryos and Analysis of Morphologic
Changes--
Embryos from matings of hyperglycemic or control
Bax / or +/ females with Bax +/
males or Bax +/+ females with Bax +/+ males, were
recovered on day 14 of gestation counting the day of plug as day 0. The
mice were anesthetized with a lethal dose of pentobarbital, and the
abdomen was opened immediately. The uterus was removed and examined for
resorption sites and fetuses. The fetuses were freed of membranes and
examined carefully under a dissecting microscope for evidence of
external anomalies. The following morphologic criteria were examined:
body rotation, closure of the neural tube, and appearance of heart,
head, mouth, and abdominal wall. Embryos were categorized as
morphologically normal or as showing minor or major malformations as
described previously (15). Normal embryos exhibited correct body
flexure and closure of both the anterior and posterior neural pore.
Embryos were classified as having a minor malformation if they
exhibited a small malrotation or a delayed closure of a single neural
pore. Embryos were recorded as having a major malformation if they
demonstrated severe malrotation, an abnormally open neural tube, or a
cardiac or other gross malformation. An average malformation score was
calculated for each experimental condition, where normal embryos and
embryos with minor and major malformations were assigned individual
scores of 0, 1, and 10 respectively.
Because Bax / mice had to be mated with
Bax +/ males, only 50% of the fetuses should have
the null genotype. To determine whether the malformed fetuses among
these litters demonstrated a Bax +/ or /
genotype, malformed fetuses in these litters were genotyped using the
standard protocol for genotyping tail DNA with polymerase chain
reaction (14).
Statistical Analysis--
Differences between the four groups
(L-glucose, D-glucose, sense, and antisense)
among protein expression, glucose uptake, and percent TUNEL staining
were compared by one-way analysis of variance (ANOVA) coupled with
Fisher test (Statview 4.5). Differences between the diabetic and
non-diabetic Bax genotypes among glucose transport, TUNEL
staining, and resorption/malformation rates also were compared by ANOVA
coupled with the Fisher test. Results are expressed as means ± S.E. of at least three separate experiments.
 |
RESULTS |
Antisense Oligoprobe Treatment Successfully Decreases GLUT1 Protein
Expression and Function--
By Western blot analysis, protein
expression of GLUT1 was significantly lowered in response to antisense
oligoprobe exposure as compared with sense or L-glucose
control. There was a significant 46 ± 11% drop in protein
expression in the antisense group as compared with the sense group.
There was a significant 33 ± 13% drop in protein expression in
the D-glucose versus L-glucose
group. (n = 3 experiments with 280 embryos in each
group for each experiment, Fig.
1A). These findings were
confirmed by detection of less GLUT1 protein in antisense-treated
blastocysts by confocal immunofluorescence microscopy (Fig.
1B).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 1.
Antisense oligoprobe decreases GLUT1 protein
expression. A, blastocysts cultured from a 2-cell stage
in either 5-µM sense oligoprobe (S),
5-µM antisense oligoprobe (AS), 52 mM L-glucose (LG) or 52 mM D-glucose (DG) were subjected to
7.5% SDS-polyacrylamide gel electrophoresis. Each sample represents
280 embryos. PC or positive control represents purified
erythrocyte transporter GLUT1. B, fixed blastocysts cultured
under one of the four conditions listed in A were stained
with propidium iodide (red channel) and GLUT1 polyclonal
primary antibody with an FITC-labeled secondary antibody (green
channel) and visualized by confocal immunofluorescent
microscopy.
|
|
The decrease in protein expression among the embryos exposed to
antisense oligoprobes correlated with a significant decrease in
nonradioactive 2-deoxyglucose uptake into single mouse blastocysts using microfluorometric assays combined with enzymatic cycling reactions (1.254 ± 0.077 pmols/embryo/15 min antisense
(n = 32 embryos) versus 1.795 ± 0.12 sense (n = 35). Embryos cultured in
D-glucose demonstrated a similar decrease as compared with L-glucose controls (2.045 ± 0.067 L-glucose (n = 35 embryos)
versus 1.644 ± 0.070 D-glucose
(n = 33 embryos) (Fig.
2).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
Antisense oligoprobe decreases glucose
transport into the blastocyst. 2-Deoxyglucose uptake in
blastocysts exposed to the control conditions, 52 mM
L-glucose (L-glu) and sense
oligoprobe (solid bars) or to the treatment conditions, 52 mM D-glucose (D-glu) and
antisense (striped bars). Antisense or high glucose
conditions resulted in a significant decrease in glucose uptake as
measured by 2-deoxyglucose uptake. Significance between L-
and D-glucose: *, p < 0.02; between sense
and antisense: #, p < 0.01.
|
|
The decrease in deoxyglucose uptake correlated with a significant
decrease in intraembryonic free glucose levels. Embryos cultured in
antisense oligoprobe demonstrated 36% less free glucose than the
embryos cultured in sense oligoprobe (41.8 ± 4 femtomole/embryo (AS, n = 13) versus 64.8 ± 5 femtomole/embryo (S, n = 13).
Antisense Treatment Induces Apoptosis--
Culturing embryos in
the presence of GLUT1 antisense oligoprobes (n = 10 embryos) induced a high rate of apoptosis (46 ± 6% TUNEL-positive nuclei/total nuclei/embryo) at the blastocyst stage as
compared with embryos exposed to sense (7 ± 2%,
n = 6) or control media with 52 mM
L-glucose (5 ± 1%, n = 8). This high
TUNEL-positive percentage was significantly higher than control
conditions (p < 0.001) but was not significantly
different from embryos cultured in 52 mM
D-glucose (47 ± 5%, n = 7) (Fig.
3, A and B).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Antisense oligoprobe results in increased
TUNEL-stained nuclei. A, embryos cultured under one of
4 conditions, as described in the legend to Fig. 2, were examined for
TUNEL staining. The red channel represents propidium iodide
staining, the green channel represents FITC-labeled
3'-fragmented DNA. The figure shows one of a Z-series representative of
the results. B, percent TUNEL-positive nuclei demonstrating
DNA fragmentation per total embryonic nuclei. Solid bars,
control conditions (L-glucose and sense); striped
bars, test conditions (D-glucose and antisense).
Antisense or high glucose conditions resulted in a significantly
higher percentage of apoptotic nuclei (*, p < 0.001).
|
|
Lack of BAX Does Not Affect Glucose Transport but Does Protect
Against Apoptosis--
Embryos obtained from streptozotocin-induced
diabetic Bax / mice experience a significant decrease in
glucose transport (0.265 ± 0.027 pmol/embryo/15 min) compared
with embryos from non-diabetic Bax / mice (0.633 ± 0.133). This decrease in glucose transport in a diabetic state was not
significantly different from that seen among embryos from diabetic
versus non-diabetic wild-type mice (diabetic, 0.278 ± 0.038 versus control, 0.528 ± 0.062 pmol/embryo/15
min; Fig. 4).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
Lack of BAX expression does not protect
against decreased glucose uptake in response to hyperglycemia.
2-Deoxyglucose uptake in blastocysts recovered from non-diabetic or
diabetic animals from Bax +/+ mice (solid bars)
or Bax / mice (striped bars). Embryos
from Bax +/+ and / mice demonstrated a significant
decrease in glucose uptake when recovered from diabetic mothers
(*, p < 0.01).
|
|
Despite this decrease in glucose transport, blastocysts from
hyperglycemic Bax / mice fail to show any evidence of
apoptosis. Blastocysts from diabetic Bax / mice
demonstrated 7.6 ± 2.0% TUNEL-positive nuclei/total
nuclei/embryo (n = 7) as compared with non-diabetic
Bax / mice with 5.0 ± 1% (n = 15). In contrast, wild-type mice made diabetic with streptozotocin
demonstrated a significant increase in apoptotic nuclei
versus non-diabetic (48.5 ± 5.6% diabetic,
n = 7; 6.2 ± 1.6% control, n = 10) (Fig. 5, A and
B).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
Decrease in glucose transport in response to
hyperglycemia does not translate into increased apoptosis in the
blastocyst from Bax null mice. A,
blastocysts from each of 4 conditions, as described in the legend to
Fig. 4, were examined for TUNEL staining. The red channel
represents propidium iodide staining; the green channel
represents FITC-labeled 3'-fragmented DNA. The figure shows one of a
Z-series representative of the results. B, percent
TUNEL-positive nuclei demonstrating DNA fragmentation per total
embryonic nuclei. Bax +/+ mice (solid bars),
Bax / mice (striped bars). Embryos from
Bax +/+ mice demonstrated a significant increase in
TUNEL-positive nuclei when recovered from diabetic mothers (*,
p < 0.001), whereas blastocysts from diabetic
Bax / had a percentage of TUNEL-positive that was not
significantly different from non-diabetics.
|
|
Lack of Bax Expression Protects Against Diabetic
Embryopathy--
As shown in Table I,
E14 embryos from Bax / , mice made hyperglycemic
with streptozotocin demonstrated a significantly lower rate of
resorptions and malformations as compared with E14 embryos from
diabetic Bax +/ or +/+ mice. Using ANOVA, a
significantly higher percent of Bax +/ or
Bax +/+ embryos demonstrate malformations than
Bax / embryos (p < 0.001). Moreover,
the severity of the malformations from the diabetic Bax
/ mice was significantly lower than the heterozygote or wild-type
mice as reflected by the malformation score. These malformations
included micrognathia, omphalocele, cranial abnormality/neural tube
defect, or malrotation in that order of descending frequency.
Non-diabetic mice of all genotypes demonstrated similar low rates of
resorption and malformation.
 |
DISCUSSION |
These experiments demonstrate that decreased expression of GLUT1
in the mouse blastocyst caused by exposure to GLUT1 antisense oligonucleotide probes results in decreased glucose transport and an
increase in apoptosis. In addition, hyperglycemia in the Bax
/ mother causes a decrease in embryonic glucose transport at the
blastocyst stage as is seen in wild-type Bax +/+ mice. The
embryos lacking BAX expression, however, fail to undergo apoptosis. These findings demonstrate that this apoptotic event experienced in
conditions of hyperglycemia is triggered by a decrease in glucose transporter expression. Previously, we have shown in two separate reports that hyperglycemia leads to apoptosis (2) and concurrently to
decreased transporter expression (1). These findings clarify that the
two events are not unrelated parallel responses to hyperglycemia and
reveal that the decrease in glucose transport caused by hyperglycemia directly triggers a downstream BAX-dependent apoptotic
event. This conclusion is significant because the majority of studies reported, which relate diabetes and hyperglycemia to apoptosis, assume
that the high glucose triggers programmed cell death by accumulation of
intracellular glucose levels or glucotoxicity (16-18). Several studies
in a number of different cell types have shown, in accordance with our
findings, that decreased transport and metabolism of glucose modify
programmed cell death (Refs. 6, 19, and 20 and reviewed in Ref. 21).
Three cell death paradigms exist that link a decrease in glucose
transport to apoptosis. These include 1) glucose deprivation-induced
ATP depletion and stimulation of the mitochondrial death pathway
cascade (7, 22), 2) glucose deprivation-induced oxidative stress and
triggering of BAX-associated events including the JNK/MAPK signaling
pathways (8, 23-27), and 3) hypoglycemia-regulated expression of
HIF-1 , stabilization of p53 leading to an increase in p53-associated apoptosis (28, 29).
In this embryonic model, it is possible that low levels of ATP because
of decreased glucose utilization may be responsible for triggering
apoptosis. At a blastocyst stage embryonic energy metabolism changes
from the use of pyruvate via the Krebs cycle and oxidative
phosphorylation to the use of glucose via glycolysis to generate
lactate (30-32). This switch is believed to be because of anaerobic
conditions that occur at this time of implantation and result in less
efficient production of ATP (33-35). This physiologic decrease in ATP
production coupled with the hyperglycemia-induced decrease in glucose
transport and thus glucose utilization seen in embryos exposed to
hyperglycemia may act to trigger apoptosis via this paradigm.
Altered embryonic redox state may also play a role in high
glucose-induced embryonic apoptosis. In postimplantation models of
diabetes-induced malformations, it has been shown that antioxidants such as N-acetylcysteine (36), butylated hydroxytoluene
(37), and vitamins C (38) and E (15) reduce the incidence of anomalies by decreasing oxygen-free radicals during organogenesis. Two factors are different in the blastocyst model. First, we are looking at a
preimplantation event, prior to organogenesis. Second, postimplantation models support intracellular hyperglycemia, not hypoglycemia as the
cause of increased oxygen-free radicals. Similar to our blastocyst model, hyperglycemia also has been shown to induce a down-regulation of
glucose transporters leading to glucose deprivation in retinal capillary pericytes (39). High initial intracellular glucose levels in
this condition lead to accelerated elimination of reactive oxygen
species generated by glucose auto-oxidation and by the increased
NADH/NAD+ ratio (9). Intracellular glucose levels then drop
rapidly as glucose transporter expression decreases in response to the hyperglycemia. As a result of these rapid changes, reduced glutathione levels are depleted, and expression of GSH peroxidase is increased. These data indicate that the increased susceptibility of pericytes to
oxidative stress is determined by the exacerbated imbalance between
pro-oxidant factors and those factors that scavenge them in response to
hyperglycemia (9). As a result of this oxidative stress, expression of
the anti-apoptotic gene Bcl-2 decreases while BAX expression
increases, and DNA fragmentation occurs, thus linking oxidative stress
to apoptosis in this system. These events were reversed by antioxidants
and did not occur in retinal endothelial cells. It is possible that the
same mechanisms are at work in the blastocyst model, and experiments
are needed to determine whether these apoptotic events are reversible
by antioxidants.
Finally, expression of HIF-1 in response to intracellular
hypoglycemia may play a role at this stage of development. In embryonic stem cells, Carmeiliet et al. (28) have shown that
hypoglycemia or hypoxia-induced expression or HIF-1 result in
reduced proliferation and increased apoptosis (28). This adaptation is
not seen in ES cells deficient in HIF-1 expression; however,
apoptosis is induced by other agents such as cytokines. Other studies
have shown that in response to hypoxia or hypoglycemia, HIF-1
accumulates and directly associates with and stabilizes active
wild-type p53 (29). It is possible then that this increase in p53
protein is responsible for the apoptosis demonstrated in our blastocyst model. We have preliminary data to suggest that p53 may be involved in
hyperglycemia-induced apoptosis in the blastocyst as p53 / blastocysts fail to demonstrate increased TUNEL-positive nuclei in
response to hyperglycemia.2
Further studies are needed to determine whether this is related to
HIF-1 effects.
These studies also strongly suggest that this glucose-triggered
apoptosis is responsible in part for diabetes-associated malformations and late resorptions because the diabetic Bax / mouse
failed to demonstrate the adverse pregnancy outcomes seen in the
Bax +/+ and +/ mice. One emerging hypothesis for the
etiology of some diabetes-associated malformations is
hyperglycemia-induced apoptosis. In models of both pre- and
postimplantation diabetic anomalies, apoptosis has been detected in the
tissues destined to show evidence of malformations (2, 40, 41).
Although the mechanisms are not identical for these two different time points in development, the theme is the same; hyperglycemia of maternal
diabetes triggers exaggerated programmed cell death in the developing
murine embryo resulting in congenital malformations in the
postimplantation models. It appears that elevated glucose levels
disturb expression of regulatory genes in embryonic development and
cell cycle progression resulting in premature cell death of progenitor
cells and subsequently defective morphogenesis. In the postimplantation
diabetic models, alterations in apoptotic pathway-related gene
expression, specifically the transcription factor Pax-3, directly
result in neural tube, musculoskeletal, and cardiac defects (40). Two
downstream targets of Pax-3, cdc46, and Dep-1, have been determined
(42, 43); however, the upstream regulators of Pax-3 expression by
hyperglycemia are not yet clear. The mechanisms clarifying
apoptosis-induced malformations in these models have yet to be determined.
This is the first time preimplantation apoptotic events have been
linked to malformations and late resorptions. Although this BAX
dependent effect may in part be because of postimplantation anti-apoptotic events, we predict that these pregnancy outcomes are in
large part because of the drastic preimplantation differences seen
between the genotypes. This work supports our hypothesis that the
increased programmed cell death at this stage of development results in
loss of key progenitor cells in the embryo and in turn this event
manifests later in pregnancy as a pregnancy loss or congenital
malformation. Both these pregnancy outcomes are more common in women
with insulin-dependent diabetes mellitus, and these
findings may provide one possible explanation for this increased incidence.
 |
FOOTNOTES |
*
This work was supported in part by the National Institutes
of Health Grants R03 HD34693 and P60 DK30579 (to K. H. M).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of a National Institutes of Health Postdoctoral
Fellowship Grant T32-DK38496-20.
§
Recipient of a Burroughs Wellcome Fund Career Award in the
Biomedical Sciences and a Juvenile Diabetes Fund Research Award. To
whom correspondence should be addressed: Dept. of Ob/Gyn, 4911 Barnes-Jewish Hospital Plaza, 6th Floor Maternity, St. Louis, MO 63110. Tel.: 314-362-1765; Fax: 314-362-3328; E-mail: moleyk@ msnotes.wustl.edu.
Published, JBC Papers in Press, September 19, 2000, DOI 10.1074/jbc.M005508200
2
K. H. Moley, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
GLUT, facilitative
glucose transporter;
BSA, bovine serum albumin;
HIF-1 , hypoxia-inducible factor 1 ;
TUNEL, terminal dUTP nick-end labeling;
ANOVA, analysis of variance;
AS, antisense;
S, sense;
FITC, fluorescein
isothiocyanate;
JNK, c-Jun N-terminal kinase;
MAPK, mitogen-activated
protein kinase;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Moley, K. H.,
Chi, M.,
and Mueckler, M.
(1998)
Am. J. Physiol.
275,
E38-E47
|
| 2.
|
Moley, K. H.,
Chi, M. M.-Y.,
Knudson, C. M.,
Korsmeyer, S. J.,
and Mueckler, M. M.
(1998)
Nat. Med.
12,
1421-1424
|
| 3.
|
Greene, M. F.,
Hare, J. W.,
Cloherty, J. P.,
Benacerraf, B. R.,
and Soeldner, J. S.
(1989)
Teratology
39,
225-231
|
| 4.
|
The Diabetes Control and Complications Trial Research Group.
(1996)
Am. J. Obstet. Gynecol.
174,
1343-1353
|
| 5.
|
Hawthorne, G.,
Robson, S.,
Ryall, E. A.,
Sen, D.,
Roberts, S. H.,
and Ward Platt, M. P.
(1997)
BMJ
315,
279-281
|
| 6.
|
Kan, O.,
Baldwin, S. A.,
and Whetton, A. D.
(1994)
J. Exp. Med.
180,
917-921
|
| 7.
|
Bialik, S.,
Cryns, V. L.,
Drincic, A.,
Miyata, S.,
Wollowick, A. L.,
Srinivasan, A.,
and Kitsis, R. N.
(1999)
Circ. Res.
85,
403-414
|
| 8.
|
Deckwerth, T. L.,
Easton, R. M.,
Knudson, C. M.,
Korsmeyer, S. J.,
and Johnson, E. M., Jr.
(1998)
Exp. Neurol.
152,
150-162
|
| 9.
|
Liu, X.,
He, Z.,
Yanoff, M.,
Jian, B.,
and Ye, X.
(1998)
Investig. Ophthalmol. Vis. Sci.
39,
1535-1545
|
| 10.
|
Pantaleon, M.,
Harvey, M. B.,
Pascoe, W. S.,
James, D. E.,
and Kaye, P. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3795-3800
|
| 11.
|
Chi, M. M.,
Manchester, J. K.,
Basuray, R.,
Mahendra, S.,
Strickler, R. C.,
McDougal, D. B., Jr.,
and Lowry, O. H.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10023-10025
|
| 12.
|
Brison, D. R.,
and Shultz, R. M.
(1996)
Mol. Reprod. Dev.
44,
171
|
| 13.
|
Moley, K. H.,
Vaughn, W. K.,
DeCherney, A. H.,
and Diamond, M. P.
(1991)
J. Reprod. Fertil.
93,
325-332
|
| 14.
|
Knudson, C. M.,
Tung, K. S.,
Tourtellotte, W. G.,
Brown, G. A.,
and Korsmeyer, S. J.
(1995)
Science
270,
96-99
|
| 15.
|
Siman, C. M.,
and Eriksson, U. J.
(1997)
Diabetes
46,
1054-1061
|
| 16.
|
Di Wu, Q.,
Wang, J. H.,
Fennessy, F.,
Redmond, H. P.,
and Bouchier-Hayes, D.
(1999)
Am. J. Physiol.
277,
C1229-C1238
|
| 17.
|
Baumgartner-Parzer, S. M.,
Wagner, L.,
Pettermann, M.,
Grillari, J.,
Gessl, A.,
and Waldhausl, W.
(1995)
Diabetes
44,
1323-1327
|
| 18.
|
Donath, M. Y.,
Gross, D. J.,
Cerasi, E.,
and Kaiser, N.
(1999)
Diabetes
48,
738-744
|
| 19.
|
Berridge, M. V.,
Tan, A. S.,
McCoy, K. D.,
Kansara, M.,
and Rudert, F.
(1996)
J. Immunol.
156,
4092-4099
|
| 20.
|
Li, W.,
Liu, X.,
He, Z.,
Yanoff, M.,
Jian, B.,
and Ye, X.
(1998)
Investig. Ophthalmol. Vis. Sci.
39,
1535-1543
|
| 21.
|
Moley, K. H.,
and Mueckler, M. M.
(2000)
Apoptosis
5,
99-105
|
| 22.
|
Saikumar, P.,
Dong, Z.,
Patel, Y.,
Hall, K.,
Hopfer, U.,
Weinberg, J. M.,
and Venkatachalam, M. A.
(1998)
Oncogene
17,
3401-3415
|
| 23.
|
Malhotra, R.,
and Brosius, F. C., III
(1999)
J. Biol. Chem.
274,
12567-12575
|
| 24.
|
Lin, Z.,
Weinberg, J. M.,
Malhotra, R.,
Merritt, S. E.,
Holzman, L. B.,
and Brosius, F. C., III
(2000)
Am. J. Physiol.
278,
E958-E966
|
| 25.
|
Blackburn, R. V.,
Spitz, D. R.,
Liu, X.,
Galoforo, S. S.,
Sim, J. E.,
Ridnour, L. A.,
Chen, J. C.,
Davis, B. H.,
Corry, P. M.,
and Lee, Y. J.
(1999)
Free Radic. Biol. Med.
26,
419-430
|
| 26.
|
Lee, Y. J.,
Galoforo, S. S.,
Berns, C. M.,
Tong, W. P.,
Kim, H. R.,
and Corry, P. M.
(1997)
J. Cell Sci.
110,
681-686
|
| 27.
|
Greenlund, L. J.,
Deckwerth, T. L.,
and Johnson, E. M., Jr.
(1995)
Neuron
14,
303-315
|
| 28.
|
Carmeliet, P.,
Dor, Y.,
Herbert, J. M.,
Fukumura, D.,
Brusselmans, K.,
Dewerchin, M.,
Neeman, M.,
Bono, F.,
Abramovitch, R.,
Maxwell, P.,
Koch, C. J.,
Ratcliffe, P.,
Moons, L.,
Jain, R. K.,
Collen, D.,
Keshert, E.,
and Keshet, E.
(1998)
Nature
394,
485-490
|
| 29.
|
An, W. G.,
Kanekal, M.,
Simon, M. C.,
Maltepe, E.,
Blagosklonny, M. V.,
and Neckers, L. M.
(1998)
Nature
392,
405-408
|
| 30.
|
Brison, D. R.,
and Leese, H. J.
(1994)
Zygote
2,
69-77
|
| 31.
|
Martin, K. L.,
and Leese, H. J.
(1995)
Mol. Reprod. Dev.
40,
436-443
|
| 32.
|
Brinster, R. L.,
and Thomson, J. L.
(1966)
Exp. Cell Res.
42,
308-315
|
| 33.
|
Leese, H. J.
(1995)
Hum. Reprod. Update
1,
63-72
|
| 34.
|
Wales, R. G.
(1986)
J. Reprod. Fertil.
76,
717-725
|
| 35.
|
Leese, H. J.
(1991)
in
Early Embryo Development and Paracrine Relationships. UCLA Symposia on Molecular and Cellular Biology
(Wiley, L. M.
, and Heyner, S., eds)
, p. 117, Wiley-Liss, NY
|
| 36.
|
Wentzel, P.,
and Eriksson, U. J.
(1998)
Diabetes
47,
677-684
|
| 37.
|
Eriksson, U. J.,
and Siman, C. M.
(1996)
Diabetes
45,
1497-1502
|
| 38.
|
Siman, C. M.,
and Eriksson, U. J.
(1997)
Diabetologia
40,
1416-1424
|
| 39.
|
Mandarino, L. J.,
Finlayson, J.,
and Hassell, J. R.
(1994)
Investig. Ophthalmol Vis. Sci.
35,
964-972
|
| 40.
|
Phelan, S. A.,
Ito, M.,
and Loeken, M. R.
(1997)
Diabetes
46,
1189-1197
|
| 41.
|
Homma, S.,
Yaginuma, H.,
and Oppenheim, R. W.
(1994)
J. Comp. Neurol.
345,
377-395
|
| 42.
|
Hill, A. L.,
Phelan, S. A.,
and Loeken, M. R.
(1998)
Dev. Genes Evol.
208,
128-134
|
| 43.
|
Cai, J.,
Phelan, S. A.,
Hill, A. L.,
and Loeken, M. R.
(1998)
Diabetes
47,
1803-1805
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Zhao, J. L. Coloff, E. C. Ferguson, S. R. Jacobs, K. Cui, and J. C. Rathmell
Glucose Metabolism Attenuates p53 and Puma-dependent Cell Death upon Growth Factor Deprivation
J. Biol. Chem.,
December 26, 2008;
283(52):
36344 - 36353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Han, R. Vassena, M. M. Y. Chi, S. Potireddy, M. Sutovsky, K. H. Moley, P. Sutovsky, and K. E. Latham
Role of glucose in cloned mouse embryo development
Am J Physiol Endocrinol Metab,
October 1, 2008;
295(4):
E798 - E809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. Kim and K. H Moley
Paternal effect on embryo quality in diabetic mice is related to poor sperm quality and associated with decreased glucose transporter expression
Reproduction,
September 1, 2008;
136(3):
313 - 322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tran, Y.-W. Chen, I. Chenier, J. S.D. Chan, S. Quaggin, M.-J. Hebert, J. R. Ingelfinger, and S.-L. Zhang
Maternal Diabetes Modulates Renal Morphogenesis in Offspring
J. Am. Soc. Nephrol.,
May 1, 2008;
19(5):
943 - 952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Jacobs, C. E. Herman, N. J. MacIver, J. A. Wofford, H. L. Wieman, J. J. Hammen, and J. C. Rathmell
Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways
J. Immunol.,
April 1, 2008;
180(7):
4476 - 4486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Wofford, H. L. Wieman, S. R. Jacobs, Y. Zhao, and J. C. Rathmell
IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival
Blood,
February 15, 2008;
111(4):
2101 - 2111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wyman, A. B. Pinto, R. Sheridan, and K. H. Moley
One-Cell Zygote Transfer from Diabetic to Nondiabetic Mouse Results in Congenital Malformations and Growth Retardation in Offspring
Endocrinology,
February 1, 2008;
149(2):
466 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Davidson, H. Northrup, T. M. King, J. M. Fletcher, I. Townsend, G. H. Tyerman, and Kit Sing Au
Genes in Glucose Metabolism and Association With Spina Bifida
Reproductive Sciences,
January 1, 2008;
15(1):
51 - 58.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Eng, R. A. Sheridan, A. Wyman, M. M.-Y. Chi, K. P. Bibee, E. S. Jungheim, and K. H. Moley
AMP Kinase Activation Increases Glucose Uptake, Decreases Apoptosis, and Improves Pregnancy Outcome in Embryos Exposed to High IGF-I Concentrations
Diabetes,
September 1, 2007;
56(9):
2228 - 2234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhao, B. J. Altman, J. L. Coloff, C. E. Herman, S. R. Jacobs, H. L. Wieman, J. A. Wofford, L. N. Dimascio, O. Ilkayeva, A. Kelekar, et al.
Glycogen Synthase Kinase 3{alpha} and 3{beta} Mediate a Glucose-Sensitive Antiapoptotic Signaling Pathway To Stabilize Mcl-1
Mol. Cell. Biol.,
June 15, 2007;
27(12):
4328 - 4339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Zheng, R. Vassena, and K. E. Latham
Effects of in vitro oocyte maturation and embryo culture on the expression of glucose transporters, glucose metabolism and insulin signaling genes in rhesus monkey oocytes and preimplantation embryos
Mol. Hum. Reprod.,
June 1, 2007;
13(6):
361 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K Riley and K. H Moley
Glucose utilization and the PI3-K pathway: mechanisms for cell survival in preimplantation embryos.
Reproduction,
May 1, 2006;
131(5):
823 - 835.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. B. Dansen, J. Whitfield, F. Rostker, L. Brown-Swigart, and G. I. Evan
Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo
J. Biol. Chem.,
April 21, 2006;
281(16):
10890 - 10895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Riley, M. O. Carayannopoulos, A. H. Wyman, M. Chi, and K. H. Moley
Phosphatidylinositol 3-Kinase Activity Is Critical for Glucose Metabolism and Embryo Survival in Murine Blastocysts
J. Biol. Chem.,
March 3, 2006;
281(9):
6010 - 6019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Chang, A. N. Dale, and K. H. Moley
Maternal Diabetes Adversely Affects Preovulatory Oocyte Maturation, Development, and Granulosa Cell Apoptosis
Endocrinology,
May 1, 2005;
146(5):
2445 - 2453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. P. Fleming, W. Y. Kwong, R. Porter, E. Ursell, I. Fesenko, A. Wilkins, D. J. Miller, A. J. Watkins, and J. J. Eckert
The Embryo and Its Future
Biol Reprod,
October 1, 2004;
71(4):
1046 - 1054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Riley, J. M. Heeley, A. H. Wyman, E. L. Schlichting, and K. H. Moley
TRAIL and KILLER Are Expressed and Induce Apoptosis in the Murine Preimplantation Embryo
Biol Reprod,
September 1, 2004;
71(3):
871 - 877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. O. Carayannopoulos, A. Schlein, A. Wyman, M. Chi, C. Keembiyehetty, and K. H. Moley
GLUT9 Is Differentially Expressed and Targeted in the Preimplantation Embryo
Endocrinology,
March 1, 2004;
145(3):
1435 - 1443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Krisher
The effect of oocyte quality on development
J Anim Sci,
January 1, 2004;
82(13_suppl):
E14 - 23.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-J. Hu, L.-Y. Wang, L. A. Chodosh, B. Keith, and M. C. Simon
Differential Roles of Hypoxia-Inducible Factor 1{alpha} (HIF-1{alpha}) and HIF-2{alpha} in Hypoxic Gene Regulation
Mol. Cell. Biol.,
December 15, 2003;
23(24):
9361 - 9374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Heilig, F. Brosius, B. Siu, L. Concepcion, R. Mortensen, K. Heilig, M. Zhu, R. Weldon, G. Wu, and D. Conner
Implications of Glucose Transporter Protein Type 1 (GLUT1)-Haplodeficiency in Embryonic Stem Cells for Their Survival in Response to Hypoxic Stress
Am. J. Pathol.,
November 1, 2003;
163(5):
1873 - 1885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Wyman, M. Chi, J. Riley, M. O. Carayannopoulos, C. Yang, K. J. Coker, J. E. Pessin, and K. H. Moley
Syntaxin 4 Expression Affects Glucose Transporter 8 Translocation and Embryo Survival
Mol. Endocrinol.,
October 1, 2003;
17(10):
2096 - 2102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gao, Y. G. Chung, J. W. Williams, J. Riley, K. Moley, and K. E. Latham
Somatic Cell-Like Features of Cloned Mouse Embryos Prepared with Cultured Myoblast Nuclei
Biol Reprod,
July 1, 2003;
69(1):
48 - 56.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Wrenzycki, D. Herrmann, and H. Niemann
Timing of Blastocyst Expansion Affects Spatial Messenger RNA Expression Patterns of Genes in Bovine Blastocysts Produced In Vitro
Biol Reprod,
June 1, 2003;
68(6):
2073 - 2080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hinck, J.P. Thissen, and R. De Hertogh
Identification of Caspase-6 in Rat Blastocysts and Its Implication in the Induction of Apoptosis by High Glucose
Biol Reprod,
May 1, 2003;
68(5):
1808 - 1812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Loberg, E. Vesely, and F. C. Brosius III
Enhanced Glycogen Synthase Kinase-3beta Activity Mediates Hypoxia-induced Apoptosis of Vascular Smooth Muscle Cells and Is Prevented by Glucose Transport and Metabolism
J. Biol. Chem.,
October 25, 2002;
277(44):
41667 - 41673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M.-Y. Chi, A. Hoehn, and K. H. Moley
Metabolic changes in the glucose-induced apoptotic blastocyst suggest alterations in mitochondrial physiology
Am J Physiol Endocrinol Metab,
August 1, 2002;
283(2):
E226 - E232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Pinto, M. O. Carayannopoulos, A. Hoehn, L. Dowd, and K. H. Moley
Glucose Transporter 8 Expression and Translocation Are Critical for Murine Blastocyst Survival
Biol Reprod,
June 1, 2002;
66(6):
1729 - 1733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Malhotra, Z. Lin, C. Vincenz, and F. C. Brosius III
Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose
Am J Physiol Cell Physiol,
November 1, 2001;
281(5):
C1596 - C1603.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|